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Abstract
South Africa has one of the highest burdens of TB worldwide, driven by the country’s wide-
spread prevalence of HIV, and further complicated by drug resistance. Active case finding
within the community, particularly in rural areas where healthcare access is limited, can sig-
nificantly improve diagnosis and treatment coverage in high-incidence settings. We evalu-
ated the potential health and economic consequences of implementing community-based
TB/HIV screening and linkage to care. Using a dynamic model of TB and HIV transmission
over a time horizon of 10 years, we compared status quo TB/HIV control to community-
based TB/HIV screening at frequencies of once every two years, one year, and six months.
We also considered the impact of extending IPT from 36 months for TST positive and 12
months for TST negative or unknown patients (36/12) to lifetime use for all HIV-infected
patients. We conducted a probabilistic sensitivity analysis to assess the effect of parameter
uncertainty on the cost-effectiveness results. We identified four strategies that saved the
most life years for a given outlay: status quo TB/HIV control with 36/12 months of IPT and
TB/HIV screening strategies at frequencies of once every two years, one year, and six
months with lifetime IPT. All of these strategies were very cost-effective at a threshold of
$6,618 per life year saved (the per capita GDP of South Africa). Community-based TB/HIV
screening with linkage to care is therefore very cost-effective in rural South Africa.
Introduction
South Africa has the highest incidence of TB/HIV co-infection in the world [1]. Recent efforts
to mitigate the TB/HIV co-epidemic have focused on integrating TB and HIV control within
the healthcare setting, including screening identified TB patients for HIV and HIV patients for
TB, providing isoniazid preventive therapy (IPT) to individuals enrolled in HIV care, and
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expanding antiretroviral therapy (ART) eligibility to individuals with CD4+ cell counts below
500 cells per milliliter [1, 2]. However, access to healthcare in much of South Africa is limited
due to insufficient resources, particularly in rural areas. Active case finding for TB and HIV
within the community, compared to the currently implemented passive case finding that
requires individuals to seek care themselves, has the potential to identify additional cases [3–
9], thereby improving clinical outcomes and reducing transmission.
Studies have shown that community-based HIV testing with point-of-care CD4+ cell count
testing is very cost-effective for HIV control in settings with high incidence, and can effectively
link eligible HIV-positive individuals to ART [6, 8]. However, the combination of TB/HIV
screening and linkage to TB and HIV care has not been previously evaluated. Integration of
both TB and HIV control is particularly important in settings with high rates of co-infection,
because the incidence of each disease is dependent on the incidence of the other. Diagnostic
tests for TB are more expensive than HIV tests, and TB/HIV screening requires more provider
and patient time than HIV screening alone, increasing the cost per person screened [10].
Beyond diagnosis, linkage to care requires determining eligibility for treatment (via CD4+ cell
count for HIV and drug resistance testing for TB) and ensuring that patients enroll in the
appropriate treatment, including IPT for patients with HIV. ART is important for both TB
and HIV control, because HIV is a driver of TB disease in South Africa and 80% of TB cases
are co-infected with HIV [9]. Integrated TB/HIV control is therefore requisite for addressing
the TB/HIV co-epidemic.
To determine the cost-effectiveness of community-based TB and HIV screening and link-
age to care in rural South Africa, we developed a mathematical model that incorporates the
dynamics of both TB and HIV infection and treatment, as well as economic resource utiliza-
tion and health burden. We parameterized the model with clinical and epidemiological data
from South Africa to predict the number of TB, HIV, MDR-TB, and XDR-TB cases averted, as
well as the number of life years saved, as a result of the screening program over a 10-year time
horizon. We considered TB/HIV screening frequencies of once every two years, one year, and
six months. Analyzed from the perspective of the South African Department of Health, we
found that community-based TB/HIV screening with linkage to care was very cost-effective.
Materials and Methods
Mathematical model
To examine the potential impact of community-based TB/HIV screening and linkage to care
over a 10-year period, we extended our previous model of TB and HIV transmission in a rural
area of South Africa [9] to include healthcare costs and years of life saved. We additionally
updated the model parameters to reflect the most current data for TB and HIV incidence and
treatment coverage [11, 12]. We modeled drug-sensitive TB, MDR-TB, and XDR-TB, includ-
ing acquired and amplified drug resistance, self-cure, strain fitness, exogenous re-infection,
and mortality [13], and parameterized our model using data from clinical and epidemiological
studies (Table 1 and Table I in S1 Text).
In line with other models of TB infection [14], latent infections are stratified into rapid or
slower progression. Individuals progress from latent infection to active infectious or non-
infectious TB disease. Non-infectious individuals can become infectious over time [15, 16],
and consistent with clinical studies, a small percentage of smear-negative patients are catego-
rized as infectious [17]. The effectiveness of TB treatment is determined by drug efficacy,
adherence, and default [18]. Individuals who receive effective treatment recover from active
disease, while individuals who are ineffectively treated remain infectious and are at risk for
acquired or amplified resistance [19]. A small proportion of patients with active TB or
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Table 1. Diagnostic, treatment, and cost parameters.
Parameter Additional
Specifications
Base Case Value
(Range)
Reference
Status quo TB diagnosis and treatment
Status quo case detection rate (per year) 72.5% (60–90%) [11]
Bacteriologic coverage 80% (80–100%) [29]
Proportion of TB cases that are infectious HIV- 65% [13]
HIV+ 30% [13]
HIV+ on ART 55% [13]
Sensitivity symptom questionnaire HIV- 69% [48]
HIV+ 79% [49]
Specificity symptom questionnaire HIV- 61% [48]
HIV+ 49.6% [49]
Negative predictive value symptom questionnaire (assuming 5% TB prevalence
among HIV+)
HIV+ 97.84% [2, 49]
Sensitivity Xpert for TB detection Infectious TB 98.3% [65]
Noninfectious TB 76.9% [65]
Specificity Xpert for TB detection 99.2% (98.2–99.7) [65]
Sensitivity Xpert for rifampicin resistance detection 94.4% [65]
Specificity Xpert for rifampicin resistance detection 98.1 (96.6–99%) [65]
Sensitivity culture Infectious TB 100% [32]
Noninfectious TB 68% [32]
Specificity culture 100% [32]
Efficacy of first-line treatment
DS TB HIV- 77% [2]
HIV+ 69% [2]
HIV+ on ART 75% [2, 26–28]
MDR-TB HIV- 47% [13, 16, 66,
67]
HIV+ 30% [13, 16, 66,
67]
HIV+ on ART 42% [13, 16, 66,
67]
Efficacy of second-line treatment
MDR-TB HIV- 67% [13, 16, 66–
68]
HIV+ 45% [13, 16, 66–
68]
HIV+ on ART 60% [13, 16, 66–
68]
XDR-TB HIV- 54% [13, 66, 69]
HIV+ 36% [13, 66, 69]
HIV+ on ART 49% [13, 66, 69]
Default between drug resistant TB diagnosis and treatment initiation (proportion) MDR-TB outpatient 15% (0–24%) [32, 50]
MDR/XDR-TB inpatient 50% (29–73%) [33]
Default from TB treatment
First-line and decentralized second-line DS and MDR-TB 7% (0–50%) [50, 70]
Inpatient second-line XDR-TB 28% (0–50%) [33, 71, 72]
Status quo TB diagnostic costs (per patient)
Baseline screening $43.12 (32.22–73.11) [10, 73]
MDR/XDR-TB suspect $118.18 (92.55–222.50) [10, 73]
(Continued )
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ineffective treatment may also self-cure and return to a latently infected state [20]. Patients
who successfully complete treatment and recover may relapse to active disease [20]. Both
recovered and latently infected individuals can be exogenously re-infected with drug-sensitive
or resistant TB, contingent upon partial immunity and the time-dependent risk of infection
[21].
We modeled the early and late stages of HIV disease, mortality, and prevalence-dependent
behavior change, as well as ART initiation and default. HIV-negative individuals can become
infected with HIV at a rate proportional to the prevalence of HIV in the population [11, 22].
Consistent with clinical recommendations in 2015, HIV-infected individuals with CD4+ cell
count below 500 cells per milliliter are eligible to initiate ART [23], but only a proportion of
Table 1. (Continued)
Parameter Additional
Specifications
Base Case Value
(Range)
Reference
TB treatment and healthcare costs (monthly)
First-line TB treatment and healthcare $271.29 (269.54–
274.49)
[10, 73]
Second-line TB treatment and healthcare
MDR-TB $298.30 (164.74–
298.30)
[10, 73]
XDR-TB $1,073.13 (518.10–
1,073.13)
[10, 73]
Status quo HIV diagnosis and treatment
Status quo ART coverage 52% (20–80%) [38]
Default from ART 9.1% (0–50%) [35]
Status quo HIV diagnostic costs (per patient) $28.80 (22.92–28.80) [8, 74]
HIV treatment and healthcare costs (monthly)
Not in healthcare $54.40 (54.40–93.19) [74–77]
In healthcare, not on ART $102.56 (102.56–
141.35)
[74–77]
In healthcare, on ART $78.49 (78.49–161.65) [74–77]
IPT
Percentage of eligible patients initiating IPT following screening 31% (20–80%) [6, 35, 36]
Default from IPT 9.1% (0–50%) [37]
Efficacy 100% (22–100%) [15, 47]
Adherence 87% (21–87%) [47, 78]
IPT Costs (monthly) $3.30 (3.21–3.30) [79]
TB/HIV screening
Acceptance of screening 70% (25–100%) [6, 8, 80, 81]
Percentage of eligible patients initiating ART and IPT following diagnosis 31% (20–80%) [6, 8, 80, 81]
Percentage of ART ineligible patients initiating IPT following screening 31% (20–80%) [6, 8, 80, 81]
Percentage of patients initiating first-line and decentralized second-line TB treatment
following diagnosis
85% (50–100%) [32]
Percentage of patients initiating inpatient second-line TB treatment following
diagnosis
50% (0–70%) [33]
TB/HIV screening costs (per patient)
TB positive and HIV+ $205.30 (97.22–267.13) [6, 8, 10]
TB positive $165.84 (82.02–227.57) [6, 8, 10]
HIV+ $101.19 (24.21–163.02) [6, 8, 10]
TB negative and HIV- $45.57 (10–120) [6, 8, 10]
doi:10.1371/journal.pone.0165614.t001
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actually begin ART [11, 22]. HIV-infected individuals who are co-infected with active TB may
also start ART, regardless of CD4+ cell count [23].
We take into account both the effect of HIV and ART on TB disease, as well as TB disease
on HIV pathogenesis, such that disease progression and mortality rates depend on whether an
individual is co-infected [24]. Overall, HIV infection increases the likelihood of progression to
primary active disease in those infected with TB, the rate at latent infection reactivates to active
disease, and mortality from TB disease [1]. Infection with HIV also reduces the efficacy of TB
treatment, as well as partial immunity to superinfection or reinfection with another TB strain
[1]. Similarly, active TB disease decreases CD4+ cell counts, speeds up progression to AIDS,
and increases mortality [24, 25]. These exacerbations between TB and HIV are mitigated by
ART [26–28].
Intervention strategies
We compared the impact of community-based TB/HIV screening and linkage to care over a
10-year time horizon on the disease incidence, mortality, and healthcare costs arising from
drug-sensitive TB, MDR-TB, XDR-TB and HIV. Specifically, we compared a total of eight
mutually exclusive strategies (Table 2).
Status quo TB and HIV detection and treatment. We evaluated the effectiveness of com-
munity-based TB/HIV screening and linkage to care relative to status quo TB and HIV control
currently implemented in rural South Africa. In the baseline scenario, individuals with TB
and/or HIV symptoms self-present to a healthcare facility for symptom detection (e.g. cough
lasting longer than two weeks, fever, night sweats, and/or weight loss), Xpert MTB/RIF (a
newer, fully automated, cartridge-based technology to rapidly diagnose both TB disease and
rifampicin resistance), sputum smear, and/or chest x-ray. We assume the status quo TB case
detection rate to be 72.5% [11]. The bacteriologic coverage (i.e. the percentage of suspected TB
patients who receive microbiologic testing) for KwaZulu-Natal is estimated to be 80% [29]. Per
South African treatment guidelines [3], patients identified as having rifampicin-sensitive active
TB disease through Xpert, as well as patients who do not receive microbiologic testing but are
suspected of having active TB disease, are enrolled in first-line therapy (the administration of
four oral antibiotics for two months and two antibiotics for at least an additional four months).
Any TB patients remaining symptomatic and/or smear positive after two to three months of
first-line therapy are suspected of TB drug resistance, and then assessed by culture and drug
susceptibility testing (DST) [30]. Although sputum culture is the gold standard for diagnosis of
active pulmonary TB disease, it can require over three months to receive the results of culture
combined with DST [31, 32]. Patients who have MDR or XDR-TB confirmed are then started
on second-line therapy for at least 24 months. Patients who are initially identified through
Table 2. Intervention strategies evaluated.
Strategy TB/HIV Control IPT Duration
Status Quo, IPT 36/12 Status quo 36/12 months
Status Quo, IPT life Status quo Lifetime
Screen 2 yr, IPT 36/12 Community-based TB/HIV screening every 2 years 36/12 months
Screen 2 yr, IPT life Community-based TB/HIV screening every 2 years Lifetime
Screen 1 yr, IPT 36/12 Community-based TB/HIV screening every year 36/12 months
Screen 1 yr, IPT life Community-based TB/HIV screening every year Lifetime
Screen 6 mo, IPT 36/12 Community-based TB/HIV screening every 6 months 36/12 months
Screen 6 mo, IPT life Community-based TB/HIV screening every 6 months Lifetime
doi:10.1371/journal.pone.0165614.t002
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Xpert as having rifampicin-resistant active TB disease are also started on second-line therapy
while awaiting confirmation by DST. Current second-line TB treatment guidelines recom-
mend home-based treatment for MDR-TB management whenever possible, where patients are
visited by a nurse for the administration of injectable drugs and supervision of oral medica-
tions over a 24-month period [33]. XDR-TB patients are hospitalized for at least the intensive
phase of their treatment [30, 33].
Following HIV diagnosis, individuals are referred to an HIV clinic to receive a CD4+ cell
count to determine their eligibility for ART, but it is estimated that 15% to 45% of patients do
not follow-up for this evaluation [34, 35]. Of those who are determined to be ART-eligible
(CD4+ cell count 500 cells per milliliter), only around half start treatment [35, 36], and
about 25% of those individuals default within three years [37]. We assume the current coverage
of ART and IPT to be 52% [38–40]. While the current South African guidelines recommend
ART for individuals with a CD4+ cell count below 500 cells per milliliter, we additionally con-
sidered the scenario where all HIV-infected individuals were eligible for ART regardless of
CD4+ cell count, as has recently been demonstrated to be effective at reducing overall HIV
incidence in a population [39, 40].
The South African Department of Health recommends 36 months of IPT for TST positive
individuals and 12 months for TST negative or unknown individuals (from hereon forth
abbreviated as 36/12 months) [34, 41, 42] to treat latent infection and prevent progression to
active TB [43]. IPT is typically initiated simultaneously with ART [44, 45]. We additionally
considered the scenario where IPT was given to HIV-positive individuals for the entire dura-
tion of their lives, as has been recently recommended by the WHO [46]. We assumed individu-
als treated with IPT and adherent to treatment were protected from infection with or latent
reactivation of drug-susceptible TB for the duration of the IPT, dependent on treatment effi-
cacy (22–100%) and patient adherence (21–87%), and that IPT does not prevent the reactiva-
tion or transmission of drug resistant TB [15, 42, 47]. For the status quo scenario, we
additionally assumed that only patients who initiated ART received IPT, as is currently imple-
mented in South Africa [45], and that all patients on ART receive IPT. Upon IPT completion,
individuals return to baseline relative risk of slower TB reactivation and infection [41].
Community-based TB/HIV screening and linkage to care. We model a community-
based TB/HIV screening and linkage to care program that combines HIV testing and counsel-
ing with TB testing [9]. TB/HIV screening is offered and administered to any individual within
the community who accept TB or HIV testing, with acceptance rates between 70% and 100%
[6, 8]. As the first step in this community-based intervention, a questionnaire is used to screen
individuals for TB symptoms (sensitivity of 69–79%) [48, 49]. Sputum is then collected from
symptomatic individuals for Xpert, culture, and DST (sensitivity of 68–100%) [32]. Individuals
diagnosed by Xpert and/or culture are linked to the appropriate first- or second-line TB treat-
ment, with 85% of individuals starting treatment [32, 50]. Currently Xpert technology can
only detect rifampicin resistance, and thus XDR-TB diagnoses can only be made after waiting
two months for the DST results. We additionally considered the scenario where Xpert could
detect resistance to second-line drugs and therefore be used to rapidly diagnose XDR-TB.
Individuals are also given a rapid HIV antibody test (sensitivity of 98.2–100%) [51]. Those
who test positive have their result confirmed by a second rapid HIV test, and then have a
point-of-care CD4+ cell count performed to immediately determine their ART eligibility sta-
tus. If eligible, patients are linked to their local ART clinic for ARV treatment and IPT initia-
tion, with approximately 31% of individuals identified as eligible initiating ART and IPT [6, 8].
We assume individuals with a CD4+ cell count less than 500 cells per milliliter to be eligible
for ART, as has been recommended by South African ART guidelines [52]. We additionally
Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa
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considered the scenario where all HIV-infected individuals were eligible for ART, irrespective
of CD4+ cell count [39, 40].
Individuals not yet eligible for ART (with a CD4+ cell count greater than 500 cells per milli-
liter) are linked to their local ART clinic for IPT, as well as regular CD4+ cell count monitoring
[6, 8]. We considered two different approaches to IPT administration: a) 36/12 months of IPT,
reflecting current South African guidelines for IPT administration; and b) lifetime IPT for all
HIV patients, reflecting recent changes to WHO recommendations and findings that lifetime
IPT may greatly reduce TB burden [46, 53].
The WHO states that there is not sufficient evidence to conclude that IPT administration
increases MDR-TB incidence via the generation of isoniazid mono-resistance [46], so we
assume that neither status quo IPT nor an increase in IPT coverage via the TB/HIV screening
intervention will increase the incidence of MDR-TB. However, some predictions have been
made that isoniazid mono-resistance may become highly prevalent after 50 or more years of
IPT, thus increasing the burden of MDR and/or XDR-TB [15, 54]. Although the time horizon
for our analysis is only 10 years, in a sensitivity analysis we also consider the “worst case” sce-
nario whereby the community-based TB/HIV screening immediately causes 100% of the mod-
eled population to become resistant to isoniazid, thus decreasing the efficacy of first-line TB
treatment from 77% to 65% and increasing the probability that first-line treatment failures
acquire MDR-TB from 3.8% to 61% [55]. While this worst case scenario is unrealistically pessi-
mistic, and thus is not proposed as a likely possibility, it provides an upper bound on any
potential increases in MDR- and XDR-TB incidence and thus on the costs that could arise
from expanding IPT coverage.
Each modeled TB/HIV screening team consists of a professional nurse, two field health
workers, and three counselors who screen between 1,800 and 4,800 individuals annually at
community sites [9], costing between $61.83 and $23.18 per person screened, including the
cost of a TB symptom questionnaire and rapid HIV test. We conservatively assume $61.83 per
person screened as our base case cost, but vary the screening cost in the sensitivity analysis. In
some settings, trained community health workers have been comparably effective at testing
and linking individuals to HIV care as counselors, totaling as little as $6 per person screened
[6]. In the sensitivity analysis, we additionally vary the rates of linkage to care to reflect any dif-
ferences that might arise in other settings. The South African Department of Health aims to
screen all individuals for TB once per year [3], which we incorporate as the base case, but also
consider screening frequencies of once every two years, once every year, and once every six
months.
Health outcomes and costs
We considered the lifetime costs of TB and HIV detection and treatment among 90,000 adults
in a rural South African setting. We performed the analysis over a 10-year time horizon from
the perspective of the South African Department of Health, which is typically responsible for
all medical costs in rural settings. Health burden was estimated with regard to the number of
life years saved by an intervention strategy over the course of the lifetimes of the individuals in
the population modeled. Costs and life years were discounted at an annual rate of 3%, follow-
ing WHO guidelines [56]. Costs were presented in 2015 US dollars (US$).
Cost-effectiveness
We calculated the incremental cost-effectiveness ratio (ICER) of the community-based TB/
HIV screening and linkage to treatment strategies detailed above. The ICER of each strategy
measures the additional cost per life year saved as the frequency of TB/HIV screening and/or
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the duration of IPT is increased. In accordance with WHO guidelines, we classified an inter-
vention strategy as “very cost-effective” if its incremental cost-effectiveness ratio (ICER) was
less than the South African per capita GDP in 2015 ($6,618) and as “cost-effective” if the ICER
was less than three times the per capita GDP ($19,854) [56, 57]. Strategies with ICERs below
the threshold for cost-effectiveness can be considered to be preferred or “economically effi-
cient” strategies. Given that multiple strategies may be classified as cost-effective, the choice
regarding which strategy should be implemented will ultimately depend on the Department of
Health’s “willingness-to-pay” for each additional year of life saved. A strategy is considered
“dominated,” (i.e. not optimal) if it costs more than an alternative strategy that is as or more
effective.
Uncertainty and sensitivity analysis
To assess the impact of parameter uncertainty on our cost-effectiveness analysis and to esti-
mate the likelihood that a strategy would be optimal at a given willingness-to-pay threshold,
we performed a probabilistic sensitivity analysis [58]. We assigned probability distributions to
all parameters and costs by fitting the 95% confidence interval of beta or gamma distributions
to plausible ranges from clinical and epidemiological data (ranges are shown in Table 1 and
Table I in S1 Text; uncertainty distributions are specified in Table II in S1 Text). Samples were
drawn from these parameter distributions 1,000 times using Latin hypercube sampling and
run through the model to project distributions of intervention cost and life years saved for
each strategy. Net health benefits were calculated from the cost and life years saved distribu-
tions as the difference between the average health benefit of an intervention strategy (i.e. life
years saved) and the average intervention and healthcare costs, divided by the threshold cost-
effectiveness ratio [59]. We calculated the net health benefit of each strategy across a range of
willingness-to-pay thresholds. From this, we found the probability that a given scenario had
the greatest net health benefit compared to its alternatives at a given level of willingness-to-
pay. We used these probabilities to generate cost-effectiveness acceptability curves that quanti-
fied the uncertainty surrounding our cost-effectiveness ratio estimates. The acceptability
curves demonstrate the likelihood that a given intervention strategy saved the largest number
of life years for a given outlay (i.e. was optimal at a given willingness-to-pay threshold).
Considering South Africa’s goal of screening all individuals once per year, we also per-
formed a one-way sensitivity analysis to determine the impact of parameters on the cost-effec-
tiveness ratio of annual TB/HIV screening. Specifically, we calculated the ICER of annual TB/
HIV screening with 36/12 months of IPT and lifetime IPT at the minimum and maximum
value of each parameter (Table 1 and Table I in S1 Text) to determine whether the strategy
remained cost-effective at these extreme values.
Results
Epidemiological impacts
Under status quo TB/HIV control—including Xpert implementation, 36/12 months of IPT for
HIV-infected individuals on ART, and MDR-TB care decentralization—annual total TB inci-
dence would be reduced from 868 per 100,000 to 298 cases per 100,000 population (Fig 1A and
Table III in S1 Text) after 10 years. With the extension of ART eligibility in 2015 to individuals
with a CD4+ cell count below 500 cells per milliliter, annual HIV incidence was reduced over
10 years from 1% to 0.8% (Fig 1B and Table III in S1 Text). Annual MDR-TB incidence was
similarly reduced, from 54 to 16 cases per 100,000 population (Fig 1C and Table III in S1
Text), and annual XDR-TB incidence from 12 to 5 cases per 100,000 population (Fig 1D and
Table III in S1 Text). Expanding IPT duration to lifetime further reduced annual total TB
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incidence to 254 cases per 100,000 population after 10 years (Fig 1A and Table III in S1 Text),
but had a negligible impact on MDR-TB, XDR-TB, and HIV incidence (Fig 1B–1D and
Table III in S1 Text).
When the community-based TB/HIV screening and linkage to care intervention was imple-
mented under current 36/12 months IPT guidelines, annual total TB incidence was reduced to
between 274 per 100,000 to 233 cases per 100,000 population, for screening frequencies
between once every two years and every six months (Fig 1A and Table III in S1 Text). Annual
HIV incidence was reduced to between 0.8% and 0.6% (Fig 1B and Table III in S1 Text), corre-
sponding to screening frequencies between once every two years to once every six months.
Annual MDR-TB incidence was reduced to between 15 and 14 MDR-TB cases per 100,000
population (Fig 1C and Table III in S1 Text), while annual XDR-TB incidence fell to between
5 and 4 XDR-TB cases per 100,000 population (Fig 1D and Table III in S1 Text). When IPT
was extended to the lifetime of HIV patients, TB/HIV screening and linkage to care further
Fig 1. Epidemiological impact. Epidemiological impact of community-based TB/HIV screening and linkage to care
at frequencies of once every two years (Screen 2 yr), once every year (Screen 1 yr), and once every six months
(Screen 6 mo) relative to status quo with 36/12 months of IPT (IPT 36/12) or lifelong IPT (life IPT) on (A) total TB
incidence per 100,000 population, (B) HIV incidence (%), (C) MDR-TB incidence, and (D) XDR-TB incidence over 10
years. Data points can also be found in Table III in S1 Text.
doi:10.1371/journal.pone.0165614.g001
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reduced total TB incidence to between 208 and 153 cases per 100,000 population after 10 years
(Fig 1A and Table III in S1 Text), while negligibly impacting HIV, MDR-TB, and XDR-TB rel-
ative to TB/HIV screening with 36/12 months of IPT (Fig 1B–1D and Table III in S1 Text).
Cost-effectiveness analysis
We first estimated the additional discounted costs associated with community-based TB/HIV
screening and linkage to care, as well as the discounted life years (LYs) saved, at screening fre-
quencies of once every two years, one year, and six months, relative to status quo (Table 3).
Under status quo TB/HIV control with 36/12 months of IPT, health costs were projected to be
$225 million with 1.86 million LYs saved over the next 10 years. Extending IPT duration to
lifetime cost an additional $7.7 million and added approximately 3,000 LYs. Implementing
community-based TB/HIV screening and linkage to care, when 36/12 months of IPT were rec-
ommended, cost an additional $25.8 million to $97.3 million for screening frequencies
Table 3. Cost-effectiveness analysis. Ten year cumulative TB and HIV infections, discounted lifetime costs, discounted lifetime benefits (life years saved),
and ICERs for community-based screening and linkage to care with IPT duration of 36/12 months (IPT 36/12) and lifelong IPT (IPT life) for screening frequen-
cies once every two years (Screen 2 yr), every one year (Screen 1 yr), and six months (Screen 6 mo). Modeled population size is approximately 90,000 (a typi-
cal rural community in South Africa). LY = life years.
Total TB
Cases
DS TB
Cases
MDR TB
Cases
XDR TB
Cases
HIV
Cases
Discounted Lifetime
Costs (2015 US$)
Discounted
Lifetime LYs
ICER ($/LY)
All Strategies
Status Quo, IPT 36/12 4,189 3,878 241 71 8,359 225,249,000 1,861,000 -
Status Quo, IPT life 3,718 3,414 236 68 8,368 232,934,000 1,864,000 Weakly
Dominateda
Screen 2 yr, IPT 36/12 3,795 3,501 227 67 7,863 251,067,000 1,873,000 Weakly
Dominateda
Screen 2 yr, IPT life 3,167 2,883 220 63 7,641 265,509,000 1,885,000 1,700
Screen 1 yr, IPT 36/12 3,494 3,214 217 64 7,471 275,685,000 1,882,000 Strongly
Dominatedb
Screen 1 yr, IPT life 2,797 2,529 209 60 7,143 293,197,000 1,898,000 2,000
Screen 6 mo, IPT 36/12 3,067 2,807 201 59 6,894 322,515,000 1,895,000 Strongly
Dominatedb
Screen 6 mo, IPT life 2,336 2,088 193 55 6,513 341,250,000 1,915,000 2,800
IPT 36/12 Months Strategies Only
Status Quo, IPT 36/12 4,189 3,878 241 71 8,359 225,249,000 1,861,000 -
Screen 2 yr, IPT, 36/12 3,795 3,501 227 67 7,863 251,067,000 1,873,000 2,200
Screen 1 yr, IPT 36/12 3,494 3,214 217 64 7,471 275,685,000 1,882,000 2,700
Screen 6 mo, IPT 36/12 3,067 2,807 201 59 6,894 322,515,000 1,895,000 3,400
Lifelong IPT Strategies Only
Status Quo, IPT life 3,718 3,414 236 68 8,368 232,934,000 1,864,000 -
Screen 2 yr, IPT life 3,167 2,883 220 63 7,641 265,509,000 1,885,000 1,600
Screen 1 yr, IPT life 2,797 2,529 209 60 7,143 293,197,000 1,898,000 2,000
Screen 6 mo, IPT life 2,336 2,088 193 55 6,513 341,250,000 1,915,000 2,800
aBy convention, a strategy is considered “Weakly Dominated” if it costs more and is less effective than some combination of other strategies. Both the
“Status Quo, IPT life” and “Screen 2 yr, IPT 36/12” strategies are weakly dominated by the combination of the “Status Quo, IPT 36/12” and “Screen 2 yr, IPT
life” strategies.
bBy convention, a strategy is considered “Strongly Dominated” if it costs more and is less effective than some other strategy. The “Screen 1 yr, IPT 36/12”
strategy is strongly dominated by the “Screen 2 yr, IPT life” strategy. “The “Screen 6 month, IPT 36/12” strategy is strongly dominated by the “Screen 1 yr,
IPT life” strategy.
doi:10.1371/journal.pone.0165614.t003
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between once every two years and once every six months, while also gaining between 11,600
and 34,500 LYs, respectively. Adding TB/HIV screening to lifetime IPT cost between $32.6
million and $108.3 million more than status quo with lifetime IPT, while gaining another
20,600 to 51,400 LYs for screening frequencies of once every two years and once every six
months, respectively.
Cost-effectiveness analysis (Table 3) identified four “economically efficient” strategies (i.e.
strategies which conferred the maximal benefit for a given outlay): status quo with 36/12
months of IPT; TB/HIV screening every two years with lifetime IPT; TB/HIV screening every
year with lifetime IPT; and TB/HIV screening every six months with lifetime IPT. All three
TB/HIV screening strategies involving 36/12 months of IPT were dominated relative to the
TB/HIV screening strategies with lifetime IPT (i.e. they cost more and conferred fewer life
years than the combination of lifetime IPT strategies), as was status quo detection with lifetime
IPT relative to status quo detection with 36/12 months of IPT. ICERs estimated for the four
efficient strategies were all significantly below the South African per capita GDP of $6,618, sug-
gesting that even the most frequent program of TB/HIV screening with lifetime IPT would be
very cost-effective by South African standards. When considered separately from strategies
with lifetime IPT, all three screening strategies involving 36/12 months of IPT were very cost-
effective at a threshold of $6,618.
In the probabilistic sensitivity analysis, we calculated the probability that a given strategy
was optimal (i.e. maximizing net health benefits and number of life years saved for a given out-
lay) relative to the other strategies at different willingness-to-pay thresholds (Fig 2). Consider-
ing strategies with 36/12 months of IPT or lifetime IPT together (Fig 2A), status quo TB/HIV
control with 36/12 months of IPT had the highest probability of being the most cost-effective
option for a willingness-to-pay below $3,000 per LY. For a willingness-to-pay between $3,000
and $3,5000 per LY, annual TB/HIV screening and linkage to care with lifetime IPT had the
highest probability of being the most cost-effective strategy. TB/HIV screening and linkage to
care every six months with lifetime IPT had the highest probability of being the most cost-
effective strategy for a willingness-to-pay above $3,500 (Fig 2A). Considering strategies with
36/12 months of IPT alone (Fig 2B), status quo had the highest probability of being the most
cost-effective option for a willingness-to-pay below $4,000 per LY. For a willingness-to-pay
above $4,000 per LY, TB/HIV screening at a frequency of six months had the highest probabil-
ity of being the most cost-effective strategy. Considering just strategies with lifetime IPT (Fig
2C), status quo TB/HIV control had the highest probability of being the most cost-effective
option at a willingness-to-pay below $3,000 per LY. For a willingness-to-pay between $3,000
and $3,500 per LY, annual TB/HIV screening with 36/12 months of IPT was optimal, while
TB/HIV screening every six months with 36/12 months of IPT was optimal at a willingness-to-
pay above $3,500 per LY.
Using one-way sensitivity analysis, we investigated the extent to which the ICER for annual
TB/HIV screening and linkage to care was impacted by variation in parameters (Figs 3 and 4).
For both 36/12 months and lifetime IPT scenarios, the cost-effectiveness ratio of the screening
intervention was most sensitive to status quo ART coverage. The cost-effectiveness of screen-
ing was also sensitive to the cost per person screened (excluding the cost of TB and HIV tests),
status quo HIV prevalence, and the proportion of patients linked to HIV treatment and care.
For all parameters varied, the intervention remained very cost-effective at a threshold below
$6,618 (i.e. the per capita GDP). The ICER of annual TB/HIV screening was not sensitive to
variation in TB or IPT parameters, including status quo TB incidence or linkage to TB care.
We found that even if expanded IPT coverage increased isoniazid resistance or the sensitivity
of Xpert for detecting XDR-TB was improved, community screening interventions would
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Fig 2. Probabilistic sensitivity analysis. Acceptability curves show the probability that a given strategy provides
the greatest net health benefit at a given willingness-to-pay threshold (i.e. probability that the strategy is optimal)
for (A) all strategies, (B) only strategies with 36/12 months of IPT, and (C) only strategies with lifetime IPT. Solid
grey vertical lines indicate the thresholds $6,618 and $19,854 for “very cost-effective” and “cost-effective”,
respectively. The solid red, green, and blue lines in panel (A) represent very low percentage values, and thus are
close to zero.
doi:10.1371/journal.pone.0165614.g002
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remain cost-effective. Finally, TB/HIV screening remained very cost-effective when ART eligi-
bility was expanded to all HIV-infected individuals.
Discussion
We found that community-based TB/HIV screening with linkage to care is a very cost-effec-
tive approach for reducing the burden of both diseases in South Africa. When the intervention
was implemented over 10 years, total TB incidence was reduced to as low as 298 cases per
100,000 population and HIV incidence to 0.8%, while simultaneously decreasing both MDR
and XDR-TB incidence. For the country as a whole, this integrated community-based inter-
vention could save as many as 31.8 million life years.
The intervention remained very cost-effective even when status quo guidelines extended
IPT from 36/12 months to lifetime or expanded ART eligibility from CD4+ cell count below
500 cells per milliliter to all HIV-infected individuals. Although we found that screening strate-
gies of once every two years, once every year, or once every six months were all cost-effective,
annual screening is most practical for implementation in rural settings. Accordingly, an aim of
the South African Department of Health is to screen individuals for TB on an annual basis.
Although the intervention remained very cost-effective across entire ranges of plausible val-
ues, its cost-effectiveness was most influenced by variation in cost per person screened, as well
as status quo HIV prevalence and ART coverage. In such settings where ART coverage is high
or HIV prevalence is low, a smaller pool of untreated individuals is available in the commu-
nity. Therefore a lower return for screening effort would be expected, thus increasing the cost
per HIV positive or TB positive diagnosed and linked to care. In general, community-based
Fig 3. One-way sensitivity analysis: Standard IPT duration 36/12 months. One-way sensitivity analysis of
cost-effectiveness ratio of annual TB/HIV screening and linkage to care relative to status quo, with standard IPT
duration 36/12 months. The dashed vertical line indicates the South African per capita GDP threshold of $6,618 for
“very cost-effective”. Ranges across which parameters were varied are indicated in parentheses.
doi:10.1371/journal.pone.0165614.g003
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TB/HIV screening is best suited to settings with high prevalence of both diseases, and where
treatment coverage is suboptimal, as is the case currently in South Africa and many parts of
sub-Saharan Africa.
Although increasing the cost per person screened unsurprisingly reduced the efficiency of
the intervention, the ICER remained below the cost-effectiveness threshold for cost-effective-
ness even if screening costs were doubled beyond our base costs parameterized from pilot
implementation in rural South Africa. It is not until screening costs exceed 10 times the base
cost that the intervention would no longer be cost-effective. We found the cost-effectiveness of
annual TB/HIV screening to be robust to variation in TB incidence or treatment parameters,
as well as IPT efficacy and adherence parameters. Because TB treatment costs constitute a frac-
tion of total TB/HIV related healthcare costs, even when accounting for expensive drug resis-
tant TB diagnosis and treatment costs, the costs of integrated TB/HIV healthcare will not be
substantially affected by changes in TB costs alone. Furthermore, the cost-effectiveness of the
community-based TB/HIV screening and linkage to care program was also unaffected by
changes in status quo XDR-TB detection. While a smaller pool of undetected XDR-TB cases
would be expected if improved Xpert technology were available for status quo XDR-TB diag-
nosis, overall status quo health care costs would also rise as additional XDR-TB cases are
treated and the relative increase in cost per XDR-TB case diagnosed by the intervention would
not push the ICER past the South African cost-effectiveness threshold.
Overall, screening strategies with lifetime IPT dominated strategies of the same frequency
shorter IPT duration, supporting a South African policy change to extend IPT to lifetime. The
benefit of lifetime IPT with status quo TB/HIV control can be attributed to the reduction in
Fig 4. One-way sensitivity analysis: Lifelong IPT duration. One-way sensitivity analysis of cost-effectiveness
ratio of annual TB/HIV screening and linkage to care relative to status quo, with lifelong IPT duration (IPT life).
The dashed vertical line indicates the South African per capita GDP threshold of $6,618 for “very cost-effective”.
Ranges across which parameters were varied are indicated in parentheses.
doi:10.1371/journal.pone.0165614.g004
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drug-sensitive TB incidence achieved by extending IPT duration. Furthermore, lifetime IPT
also improves the impact of the community-based TB/HIV screening intervention in two
ways. Firstly, TB incidence is reduced via expanded IPT coverage in a population with higher
CD4+ cell counts who would otherwise not receive IPT. Secondly, patients with high CD4+
cell counts are identified and engaged in HIV care at an earlier stage of disease, minimizing
the delay in initiating ART after becoming eligible. This reduces HIV incidence, because
patients successfully treated with ART are much less likely to transmit HIV. Although this ben-
efit was slightly diminished when status quo ART eligibility was extended to all HIV-infected
individuals, community-based TB/HIV screening remained very cost-effective.
As with other modeling studies, the validity of our analysis is limited by the data available
from epidemiological and clinical studies for parameterization. Nonetheless, sensitivity and
uncertainty analyses where all model parameters were varied across plausible ranges demon-
strated that our cost-effectiveness results are robust to parameter uncertainty. TB and HIV
control in South Africa has also been rapidly evolving over the past decade, so “status quo”
control strategies, guidelines, and technologies are likely to continue improving. Therefore, we
evaluated the two most likely scenarios for South African policy change: increasing the dura-
tion of IPT administration to lifetime and expanding ART eligibility to all HIV-infected indi-
viduals, as have been recently recommended by the WHO. We additionally explored the
impact of high status quo TB and HIV treatment coverage on our cost-effectiveness results in
the sensitivity analysis.
Our results support community-based TB/HIV screening with linkage to TB and HIV care.
This intervention has the potential to substantially reduce TB and HIV incidence simulta-
neously by expanding ART, IPT, and both first- and second-line TB treatment coverage. A
number of recent studies have shown that home or community-based HIV testing and
counseling is very effective and cost-effective in rural South Africa, with the potential to sub-
stantially reduce HIV incidence and associated mortality [6, 60–64]. These studies have estab-
lished that a decentralized approach to HIV testing is not only both feasible and well accepted
by patients, but that linkage to care and ART initiation occurs with subsequent virologic sup-
pression. Our study also supports community-based HIV testing and counseling, while further
demonstrating that combining TB screening with community-based HIV screening and link-
age to care comprehensively addresses the TB/HIV co-epidemics of rural South Africa. In
addition, community-based TB/HIV screening with linkage to care remains cost-effective
under many different scenarios, including policy changes that would increase IPT duration to
the lifetime of patients or make all individuals eligible for ART. The efficiency of this inte-
grated community intervention would therefore be robust to changes in the South African TB/
HIV healthcare landscape, and would likely have applicability beyond South Africa to other
rural settings with high TB and HIV burdens.
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